test

Prostate Cancer

10
A Multinational, Phase III, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
A Randomized Open-label Phase IIa Study Evaluating Quantified Bone Scan Response Following Treatment With Radium-223 Dichloride Alone or in Combination With Abiraterone Acetate or Enzalutamide in Subjects With Castration-resistant Prostate Cancer Who Have Bone Metastases
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
A Three Arm Randomized Open-label Phase II Study of Radium-223 Dichloride 50 kBq/kg Versus 80 kBq/kg, and Versus 50 kBq/kg in an Extended Dosing Schedule in Subjects With Castration-resistant Prostate Cancer Metastatic to the Bone
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
Assessing the support care needs, quality of life and relationship satisfaction of men with prostate cancer and their spousal caregivers: a cross-culture comparison between Chinese and American couples.
Principal Investigator: Dwain Fehon
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men with Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
RTOG 0815: Randomized Trial With or Without Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer
Disease/Condition: Prostate | Prostate Cancer
Principal Investigator: Joseph Cardinale